NARI Inari Medical

Inari Medical Appoints Dana G. Mead, Jr. to Board of Directors

Inari Medical Appoints Dana G. Mead, Jr. to Board of Directors

IRVINE, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointment of Mr. Dana G. Mead, Jr. to its board of directors. Mr. Mead will serve as a member of the Compensation Committee of the board.

“We are pleased to welcome Dana as a new independent director to our board. Mr. Mead’s decades of executive operating experience leading high growth med tech businesses, will be highly valuable to Inari as we enter the next phase of our mission to treat and transform the lives of patients suffering from venous thromboembolism,” said Bill Hoffman, Inari’s Chief Executive Officer.

From May 2019 to February 2021, Mr. Mead served as President and CEO of HeartFlow, Inc., a medical device company located in Redwood City, CA. From November 2016 to May 2019, Mr. Mead served as the President and Chief Executive Officer of Beaver-Visitec International, a medical device company located in Waltham, MA. Previously, Mr. Mead was a Strategic Advisor and Partner at Kleiner Perkins Caufield & Byers, a venture capital firm, having joined the firm in May 2005 where he served until June 2016. Mr. Mead was at Guidant Corporation, a cardiovascular medical device company, from 1992 to 2005, most recently as President, Guidant Vascular Intervention. Since July 2008, Mr. Mead has served as a member of the board of directors of Inspire Medical Systems, Inc., a NYSE listed medical technology company. Since February 2010, Mr. Mead has served on the board of directors of Pulmonx Corporation, a NASDAQ listed medical device company, and since June 2007 on the board of directors of Intersect ENT, Inc., a NASDAQ listed medical device company. Mr. Mead also served on the board of directors of Teladoc, Inc., a NYSE listed telehealth platform company, from August 2011 to December 2016.

About Inari Medical, Inc.

Inari Medical, Inc. is a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of pulmonary embolism and clot in transit in the right atrium.

Investor Contact:

Westwicke Partners

Caroline Corner

Phone



EN
01/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Inari Medical

 PRESS RELEASE

Inari Medical to Present at the J.P. Morgan Healthcare Conference

Inari Medical to Present at the J.P. Morgan Healthcare Conference IRVINE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other vascular diseases, announced today that its management team is scheduled to present at the J.P. Morgan Healthcare Conference on Wednesday, January 15 at 8:15 a.m. Pacific Time. Interested parties may access a live webcast and replay of the presentation by visiting the Inari Medical investor relations . About Inari ...

 PRESS RELEASE

Inari Medical Announces Reimbursement Approval for ClotTriever® Thromb...

Inari Medical Announces Reimbursement Approval for ClotTriever® Thrombectomy System in Japan and New Distribution Partnership with Medikit Co., Ltd. Reimbursement approval supports expanded access to effective, safe thrombus removal for patients suffering from deep vein thrombosis (DVT) in Japan IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other vascular diseases, announced today that on December 1, 2024, it received national r...

 PRESS RELEASE

Inari Medical Announces Joint Venture in Greater China

Inari Medical Announces Joint Venture in Greater China IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced it has entered into a joint venture with 6 Dimensions Capital (“6 Dimensions”) and its successor fund 120 Capital, and VFLO Medical (“VFLO”), a medical device platform incubated by 6 Dimensions and 120 Capital, to provide access to Inari’s innovative technology for patients with significant unmet nee...

 PRESS RELEASE

Inari Medical to Participate in the Jefferies London Healthcare Confer...

Inari Medical to Participate in the Jefferies London Healthcare Conference IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the upcoming Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 10:00 AM Greenwich Mean Time / 5:00 AM Eastern Time. A live audio webcast and replay of the presentation may be accessed for 30 days on the “Investor Relati...

 PRESS RELEASE

PEERLESS Results Show Superiority of FlowTriever® Compared to Catheter...

PEERLESS Results Show Superiority of FlowTriever® Compared to Catheter-Directed Thrombolytics for Intermediate-Risk Pulmonary Embolism Primary endpoint win driven by both hard clinical outcomes and hospital resource utilization IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced positive results from the prospective PEERLESS Randomized Controlled Trial (RCT) comparing FlowTriever to catheter-directed th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch